On ECHEMI
Home > Drugs > Dijia Pharmaceutical Group Co., Ltd.
Dijia Pharmaceutical Group Co., Ltd.
  • Founded in:

    2013-03-07
  • Country:

    China China
  • Address:

    No. 268, Tianrun Road, Wendeng Economic Development Zone, Weihai City, Shandong Province
  • Tax NO.:

    91371081062986928J
  • Registered Funds:

    360.5 million yuan
  • Email:

Related Drugs
Flavonoids hydrochloride
Name Description Content CAS NO. Registered Holders
Flavoxate hydrochloride

Extract from the above information

More

Extract from the above information

3717-88-2 12
Candesartan cilexetil
Name Description Content CAS NO. Registered Holders
Candesartan cilexetil

Extract from the above information

More

Extract from the above information

145040-37-5 49
Loxoprofen Sodium
Name Description Content CAS NO. Registered Holders
Loxoprofen sodium

After being absorbed by the digestive tract, it is converted into active metabolites in the body. Its active metabolites exert analgesic, anti-inflammatory and antipyretic effects by inhibiting the synthesis of prostaglandins.

More

After being absorbed by the digestive tract, it is converted into active metabolites in the body. Its active metabolites exert analgesic, anti-inflammatory and antipyretic effects by inhibiting the synthesis of prostaglandins.

80382-23-6 31
Glipizide
Name Description Content CAS NO. Registered Holders
Glipizide

Glipizide is a second-generation sulfonylurea oral hypoglycemic drug. It mainly promotes the secretion of insulin by pancreatic β cells, especially the secretion of insulin stimulated by glucose; it also enhances the action of insulin, thereby effectively reducing blood glucose concentration and glycosylated hemoglobin; it can also improve hyperlipidemia, reduce triglyceride and cholesterol levels, and increase the ratio of high-density lipoprotein cholesterol in total cholesterol; it can also inhibit platelet aggregation and promote fibrinolysis, so it may have a certain preventive and therapeutic effect on vascular lesions. ① It promotes the secretion of insulin by pancreatic β cells, the prerequisite is that the pancreatic β cells still have a certain function of synthesizing and secreting insulin; ② By increasing the level of portal vein insulin or directly acting on the liver, it inhibits liver glycogenolysis and gluconeogenesis, and reduces the production and output of glucose by the liver.

More

Glipizide is a second-generation sulfonylurea oral hypoglycemic drug. It mainly promotes the secretion of insulin by pancreatic β cells, especially the secretion of insulin stimulated by glucose; it also enhances the action of insulin, thereby effectively reducing blood glucose concentration and glycosylated hemoglobin; it can also improve hyperlipidemia, reduce triglyceride and cholesterol levels, and increase the ratio of high-density lipoprotein cholesterol in total cholesterol; it can also inhibit platelet aggregation and promote fibrinolysis, so it may have a certain preventive and therapeutic effect on vascular lesions. ① It promotes the secretion of insulin by pancreatic β cells, the prerequisite is that the pancreatic β cells still have a certain function of synthesizing and secreting insulin; ② By increasing the level of portal vein insulin or directly acting on the liver, it inhibits liver glycogenolysis and gluconeogenesis, and reduces the production and output of glucose by the liver.

29094-61-9 26
Flunarizine Hydrochloride
Name Description Content CAS NO. Registered Holders
Flunarizine dihydrochloride

Extract from the above information

More

Extract from the above information

30484-77-6 25
  • 1
  • 2
  • Go to Page Go
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.